COMMUNIQUÉS West-GlobeNewswire
-
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
24/03/2026 -
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
24/03/2026 -
Earth Science Tech, Inc. (ETST) Launches MyOnlineConsultation.com, Finalizing a Fully Vertically Integrated Telehealth and Pharmacy Ecosystem
24/03/2026 -
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
24/03/2026 -
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
24/03/2026 -
TOMI Environmental Solutions Disrupts the Dairy Industry with Major Mexican Dairy Brand
24/03/2026 -
Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
24/03/2026 -
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
24/03/2026 -
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
24/03/2026 -
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
24/03/2026 -
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
24/03/2026 -
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
24/03/2026 -
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
24/03/2026 -
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
24/03/2026 -
Hyperion DeFi Enters HAUS Agreement with Silhouette
24/03/2026 -
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
24/03/2026 -
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
24/03/2026 -
Bavarian Nordic A/S – Notice Convening Annual General Meeting
24/03/2026 -
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
24/03/2026
Pages